Cargando…
Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major
Allogeneic stem cell transplantation is a cure for patients suffering from thalassemia major (TM). Historically, patients were limited by the selection of donors, while the advancement of haploidentical stem cell transplantation (haplo-SCT) has greatly expanded the donor pool. However, the outcomes...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894585/ https://www.ncbi.nlm.nih.gov/pubmed/33593080 http://dx.doi.org/10.1177/0963689721994808 |
_version_ | 1783653282993930240 |
---|---|
author | Wang, Xiaodong Zhang, Xiaoling Yu, Uet Wang, Chunjing Yang, Chunlan Li, Yue Li, Changgang Wen, Feiqiu Li, Chunfu Liu, Sixi |
author_facet | Wang, Xiaodong Zhang, Xiaoling Yu, Uet Wang, Chunjing Yang, Chunlan Li, Yue Li, Changgang Wen, Feiqiu Li, Chunfu Liu, Sixi |
author_sort | Wang, Xiaodong |
collection | PubMed |
description | Allogeneic stem cell transplantation is a cure for patients suffering from thalassemia major (TM). Historically, patients were limited by the selection of donors, while the advancement of haploidentical stem cell transplantation (haplo-SCT) has greatly expanded the donor pool. However, the outcomes of haplo-SCT in TM recipients vary between different programs. In this study, we retrospectively studied 73 pediatric TM patients (median age, 7 years; range, 3 to 14 years) who underwent haplo-cord transplantation. Both the estimated overall survival and transfusion-free survival were 95.26% (CI 95.77% to 96.23%). Neither primary nor secondary graft failures were observed. The median follow-up period was 811 days (range, 370 to 1433 days). Median neutrophil and platelet engraftment times were 22 days (range, 8 to 48 days) and 20 days (range, 8 to 99 days), respectively. Acute graft-versus-host disease (aGVHD) was observed in 52% of patients and of these, 25% developed grade III to IV aGVHD. Cord blood engraftment was associated with delayed immune recovery and increased aGVHD severity. Viral DNAemia occurred in a relatively high proportion of patients but only 7% of patients developed CMV disease, while another 7% of patients had post-transplantation lymphoproliferative disorder. Long-term complication outcomes were good. Only one patient developed extensive chronic GVHD. No surviving patients were reliant on blood transfusion by the time this manuscript was submitted. This is one of the largest studies on the outcomes of pediatric TM patients who received stem cell transplantations from alternative donors. The haplo-cord program is safe and practical for TM patients that do not have matched donors. |
format | Online Article Text |
id | pubmed-7894585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-78945852021-02-26 Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major Wang, Xiaodong Zhang, Xiaoling Yu, Uet Wang, Chunjing Yang, Chunlan Li, Yue Li, Changgang Wen, Feiqiu Li, Chunfu Liu, Sixi Cell Transplant Original Article Allogeneic stem cell transplantation is a cure for patients suffering from thalassemia major (TM). Historically, patients were limited by the selection of donors, while the advancement of haploidentical stem cell transplantation (haplo-SCT) has greatly expanded the donor pool. However, the outcomes of haplo-SCT in TM recipients vary between different programs. In this study, we retrospectively studied 73 pediatric TM patients (median age, 7 years; range, 3 to 14 years) who underwent haplo-cord transplantation. Both the estimated overall survival and transfusion-free survival were 95.26% (CI 95.77% to 96.23%). Neither primary nor secondary graft failures were observed. The median follow-up period was 811 days (range, 370 to 1433 days). Median neutrophil and platelet engraftment times were 22 days (range, 8 to 48 days) and 20 days (range, 8 to 99 days), respectively. Acute graft-versus-host disease (aGVHD) was observed in 52% of patients and of these, 25% developed grade III to IV aGVHD. Cord blood engraftment was associated with delayed immune recovery and increased aGVHD severity. Viral DNAemia occurred in a relatively high proportion of patients but only 7% of patients developed CMV disease, while another 7% of patients had post-transplantation lymphoproliferative disorder. Long-term complication outcomes were good. Only one patient developed extensive chronic GVHD. No surviving patients were reliant on blood transfusion by the time this manuscript was submitted. This is one of the largest studies on the outcomes of pediatric TM patients who received stem cell transplantations from alternative donors. The haplo-cord program is safe and practical for TM patients that do not have matched donors. SAGE Publications 2021-02-17 /pmc/articles/PMC7894585/ /pubmed/33593080 http://dx.doi.org/10.1177/0963689721994808 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Article Wang, Xiaodong Zhang, Xiaoling Yu, Uet Wang, Chunjing Yang, Chunlan Li, Yue Li, Changgang Wen, Feiqiu Li, Chunfu Liu, Sixi Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major |
title | Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major |
title_full | Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major |
title_fullStr | Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major |
title_full_unstemmed | Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major |
title_short | Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major |
title_sort | co-transplantation of haploidentical stem cells and a dose of unrelated cord blood in pediatric patients with thalassemia major |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894585/ https://www.ncbi.nlm.nih.gov/pubmed/33593080 http://dx.doi.org/10.1177/0963689721994808 |
work_keys_str_mv | AT wangxiaodong cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT zhangxiaoling cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT yuuet cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT wangchunjing cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT yangchunlan cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT liyue cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT lichanggang cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT wenfeiqiu cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT lichunfu cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor AT liusixi cotransplantationofhaploidenticalstemcellsandadoseofunrelatedcordbloodinpediatricpatientswiththalassemiamajor |